GENTIAN VIOLET: WHAT WE KNOW AND WHAT IS AHEAD OF US

被引:3
作者
Dragan, Jedrzej [1 ]
Michalak, Sylwia Sulimiera [1 ]
机构
[1] Univ Zielona, Fac Med & Hlth Sci, Gora, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2019年 / 76卷 / 03期
关键词
p53; crystal violet; gentian violet; fungal infection; bacterial infection; STAPHYLOCOCCUS-AUREUS; OROPHARYNGEAL; CANDIDIASIS; METABOLISM; INFECTION; NYSTATIN; THERAPY;
D O I
10.32383/appdr/102482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
At present, the only active substance of Gentian Violet (GV) is methylrosaniline - a triphenylmethane dye of which amino group contains 2 methyl groups. GV can be used to treat uncomplicated bacterial and/or yeast infections, support antibiotic therapy of more severe infections, but also to protect medical equipment against colonization by microorganisms. In the light of recent studies, there are many new possibilities for GV application. It has been shown to be effective in the treatment of viral infections, some chronic skin diseases and oncology. GV can induce apoptosis of tumor cells among others by elevating caspase 8, inhibiting NADPH oxidases, decreasing mitochondrial thioredoxin 2 or inhibiting STAT3/SOX2 axis. Preclinical and in vitro studies have also demonstrated GV efficacy in the treatment of breast cancer, melanoma tumors and cutaneous T-cell lymphoma. There is no unambiguous evidence indicating the toxicity of GV, whereas its safety has been proven by its long history of use, its inclusion in numerous guidelines and its legal trade and distribution with no specific approval requested in many countries around the world. The article gathers the available knowledge about GV and its potential use in the future.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [41] Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn?
    Alexander, Sarah
    Nieder, Michael
    Zerr, Danielle M.
    Fisher, Brian T.
    Dvorak, Christopher C.
    Sung, Lillian
    PEDIATRIC BLOOD & CANCER, 2012, 59 (01) : 16 - 20
  • [42] Wolbachia Horizontal Transmission Events in Ants: What Do We Know and What Can We Learn?
    Tolley, Sarah J. A.
    Nonacs, Peter
    Sapountzis, Panagiotis
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [43] Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
    Cai, Zhonglin
    Chen, Weijie
    Zhang, Jianzhong
    Li, Hongjun
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (10) : 1753 - 1764
  • [44] What We Know and Don't Know About Lyme Disease
    Donta, Sam T.
    FRONTIERS IN PUBLIC HEALTH, 2022, 9
  • [45] Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014-systematic review and meta-analysis
    Imazio, Massimo
    Brucato, Antonio
    Belli, Riccardo
    Forno, Davide
    Ferro, Silvia
    Trinchero, Rita
    Adler, Yehuda
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2014, 15 (12) : 840 - 846
  • [46] On Not Knowing What We Don't Know to Knowing What We Don't Know: Obstructive Sleep Apnea in the Transgender Community
    Earl, David C.
    Brown, Lee K.
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2019, 15 (10): : 1393 - 1395
  • [47] Maladaptive Opioid Use Behaviors and Psychiatric Illness: What Should We Do with What We Know?
    Carroll, C. Patrick
    Haythornthwaite, Jennifer
    CURRENT PAIN AND HEADACHE REPORTS, 2011, 15 (02) : 91 - 93
  • [48] Carnosine and Kidney Diseases: What We Currently Know?
    Kilis-Pstrusinska, Katarzyna
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (11) : 1764 - 1781
  • [49] Inflammatory and ImmuneMediated Myopathies, What Do We Know?
    Aleman, Monica
    VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2024, 40 (02) : 207 - 218
  • [50] An Update on the Pathogenesis of Fascioliasis: What Do We Know?
    Tanabe, Melinda B.
    Caravedo, Maria A.
    White Jr, A. Clinton
    Cabada, Miguel M.
    RESEARCH AND REPORTS IN TROPICAL MEDICINE, 2024, 15 : 13 - 24